115 related articles for article (PubMed ID: 15661559)
1. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.
Marchini S; Marrazzo E; Bonomi R; Chiorino G; Zaffaroni M; Weissbach L; Hornicek FJ; Broggini M; Faircloth GT; D'Incalci M
Eur J Cancer; 2005 Jan; 41(2):323-33. PubMed ID: 15661559
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
Zelek L; Yovine A; Brain E; Turpin F; Taamma A; Riofrio M; Spielmann M; Jimeno J; Misset JL
Br J Cancer; 2006 Jun; 94(11):1610-4. PubMed ID: 16736024
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
5. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
Hendriks HR; Fiebig HH; Giavazzi R; Langdon SP; Jimeno JM; Faircloth GT
Ann Oncol; 1999 Oct; 10(10):1233-40. PubMed ID: 10586342
[TBL] [Abstract][Full Text] [Related]
6. ET-743: more than an innovative mechanism of action.
Scotto KW
Anticancer Drugs; 2002 May; 13 Suppl 1():S3-6. PubMed ID: 12173491
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
[No Abstract] [Full Text] [Related]
8. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
9. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin: an anticancer drug from the sea.
Ganjoo KN; Patel SR
Expert Opin Pharmacother; 2009 Nov; 10(16):2735-43. PubMed ID: 19743937
[TBL] [Abstract][Full Text] [Related]
11. ET-743.
Cvetkovic RS; Figgitt DP; Plosker GL
Drugs; 2002; 62(8):1185-92; discussion 1193-4. PubMed ID: 12010079
[TBL] [Abstract][Full Text] [Related]
12. ET-743 (PharmaMar/NCI/Ortho Biotech).
Verschraegen CF; Glover K
Curr Opin Investig Drugs; 2001 Nov; 2(11):1631-8. PubMed ID: 11763168
[TBL] [Abstract][Full Text] [Related]
13. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.
Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ
PLoS One; 2009 Sep; 4(9):e6967. PubMed ID: 19742314
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
Allavena P; Signorelli M; Chieppa M; Erba E; Bianchi G; Marchesi F; Olimpio CO; Bonardi C; Garbi A; Lissoni A; de Braud F; Jimeno J; D'Incalci M
Cancer Res; 2005 Apr; 65(7):2964-71. PubMed ID: 15805300
[TBL] [Abstract][Full Text] [Related]
15. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
[TBL] [Abstract][Full Text] [Related]
16. [Progress in the studies on antitumor natural product ecteinascidin-743].
Wang Y; Liu ZZ; Chen SZ; Liang XT
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):474-8. PubMed ID: 15379280
[TBL] [Abstract][Full Text] [Related]
17. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
18. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Garcia-Carbonero R; Supko JG; Manola J; Seiden MV; Harmon D; Ryan DP; Quigley MT; Merriam P; Canniff J; Goss G; Matulonis U; Maki RG; Lopez T; Puchalski TA; Sancho MA; Gomez J; Guzman C; Jimeno J; Demetri GD
J Clin Oncol; 2004 Apr; 22(8):1480-90. PubMed ID: 15084621
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
Erba E; Bergamaschi D; Bassano L; Ronzoni S; Di Liberti G; Muradore I; Vignati S; Faircloth G; Jimeno J; D'Incalci M
Br J Cancer; 2000 May; 82(10):1732-9. PubMed ID: 10817511
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of ET-743: the French experience.
Brain EG
Anticancer Drugs; 2002 May; 13 Suppl 1():S11-4. PubMed ID: 12173489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]